New advanced isolator-based filling line delivers higher sterility assurance, reduced contamination risk, and global regulatory readiness

Sovereign Pharma announced the commissioning of its new advanced isolator-based filling line. As part of its long-term modernisation strategy, the company had planned to transition three of its filling lines to isolator-based systems. With this milestone, the first of these isolator lines is now fully commissioned and operational in production.

The isolator creates a sealed aseptic environment through glove ports, HEPA-filtered air, positive pressure containment, and vaporized hydrogen peroxide (VHP) bio-decontamination. This significantly reduces human contact, responsible for nearly 80 per cent% of contamination risks in sterile processing, resulting in higher sterility assurance, improved consistency, and reduced human error. The new isolator line features online PUPSIT (Pre-Use Post-Sterilisation Integrity Testing).

Rishad Dadachanji, Director, Sovereign Pharma, said, “Commissioning our first isolator-based filling line reflects our commitment to placing India at the forefront of sterile injectable manufacturing. We believe in going beyond compliance and setting new benchmarks. With isolator technology enabling high-volume ampoule filling for the first time in India, we reinforce our dedication to patient safety and to delivering uncompromised quality for every client we serve.”